U.S. Precision Medicine White Paper 2025

DH20931: A Novel Small Molecule Platform for All Cancers

A Revolutionary Approach to Cancer Treatment Through Ceramide Synthase 2 (CerS2) Modulation

---

Published by: U.S. Precision Medicine, Inc.
Date: July 2025
Website: www.USPrecisionMedicine.com
Status: Confidential - For Scientific Review

---

Executive Summary

The landscape of cancer treatment stands at a critical juncture. Despite decades of advancement, many cancers—particularly aggressive subtypes like Triple Negative Breast Cancer (TNBC)—remain stubbornly resistant to conventional therapies, leaving patients with limited options and poor prognoses. DH20931 represents a paradigm shift in oncological therapeutics, offering a novel mechanism of action that targets the fundamental metabolic vulnerabilities shared across virtually all cancer types.

DH20931 is a first-in-class small molecule that specifically modulates the Ceramide Synthase 2 (CerS2) pathway, a critical regulator of sphingolipid metabolism and cellular apoptosis. This compound has demonstrated remarkable efficacy across multiple preclinical models, showing an unprecedented ability to selectively eliminate cancer cells while preserving healthy tissue integrity.

Key Breakthrough Achievements:

• Universal Mechanism: Targets CerS2 pathway defects common to all tested cancer types
• Exceptional Efficacy: 80% tumor growth reduction in vivo across TNBC, Luminal B, and PDX models
• Superior Safety Profile: No significant toxicity observed in comprehensive preclinical studies
• Synergistic Potential: 5-fold enhancement of existing chemotherapy efficacy
• Broad Applicability: Demonstrated effectiveness across 60+ cancer cell lines in NCI-60 screening

---

The Unmet Medical Need

Triple Negative Breast Cancer: A Clinical Crisis

Triple Negative Breast Cancer represents one of the most aggressive and treatment-resistant forms of breast cancer, affecting approximately 300,000 patients globally each year. Unlike other breast cancer subtypes, TNBC lacks the molecular targets that make hormone therapy and HER2-targeted treatments effective. This molecular profile leaves patients with limited therapeutic options and significantly worse outcomes.

Current Treatment Limitations:

• Doxorubicin remains the mainstay therapy despite severe cardiotoxicity
• Resistance development is common and often rapid
• Limited efficacy in advanced-stage disease
• Poor quality of life due to treatment-related toxicities
• Five-year survival rates significantly lower than other breast cancer subtypes

The Broader Cancer Challenge

The challenges facing TNBC treatment reflect broader issues in oncology. Many cancers share common metabolic vulnerabilities that remain unexploited by current therapeutic approaches. The CerS2 pathway defects observed in TNBC are present across a wide spectrum of malignancies, suggesting that a therapeutic approach targeting this pathway could address multiple cancer types simultaneously.

---

Scientific Foundation: The CerS2 Pathway

Ceramide Synthase 2: A Master Regulator of Cellular Fate

Ceramide Synthase 2 (CerS2) occupies a central position in sphingolipid metabolism, a pathway critical for maintaining cellular homeostasis and regulating programmed cell death. Under normal physiological conditions, CerS2 synthesizes very long-chain fatty acid (VLCFA) ceramides, which serve as essential signaling molecules that maintain cellular integrity and promote apoptosis when cells become damaged or malignant.

The Cancer Connection: In cancer cells, transcriptional errors lead to decreased CerS2 expression, resulting in:

• Reduced ceramide synthesis
• Impaired apoptotic signaling
• Enhanced cellular survival under stress conditions
• Resistance to conventional therapies

Validation Through Genetic Evidence

The critical role of CerS2 in cancer prevention has been validated through multiple lines of evidence:

Knockout Studies: CerS2 knockout mice demonstrate increased cancer susceptibility, directly confirming the tumor suppressor function of this pathway.

Human Variants: Genetic variants affecting CerS2 function correlate with altered cancer risk profiles, providing population-level evidence for the pathway's importance.

Multi-Cancer Expression: CerS2 downregulation has been documented across multiple cancer types, including bladder, breast, liver, colorectal, ovarian, prostate, and lung cancers.

---

DH20931: Mechanism of Action

Molecular Structure and Properties

DH20931 (6,6′-dimethoxy Biisoquinoline Imidazolium) is a rationally designed small molecule that demonstrates exceptional pharmaceutical properties:

Drug-like Characteristics:

• Molecular Weight: Complies with Lipinski's Rule of Five
• Solubility: Favorable aqueous solubility (LogS)
• Permeability: Good membrane permeability
• Stability: Robust metabolic stability in liver microsome assays
• Bioavailability: Excellent absorption and bioavailability profiles

Dual Mechanism of Mitochondrial Apoptosis

DH20931 exerts its therapeutic effect through a sophisticated dual mechanism that restores the cancer cell's capacity for programmed cell death:

Mechanism 1: Lipotoxic Apoptosis Pathway

Step 1: CerS2 Activation

• DH20931 binds to and activates CerS2 at nanomolar concentrations
• As little as 100 nM doubles CerS2 enzymatic activity
• Molecular dynamics simulations confirm stable protein-drug interactions

Step 2: VLCFA Ceramide Synthesis

• Enhanced CerS2 activity stimulates synthesis of very long-chain fatty acid ceramides
• These ceramides accumulate in the endoplasmic reticulum
• Ceramide accumulation creates conditions of cellular stress

Step 3: ER Stress Response

• VLCFA ceramide accumulation triggers endoplasmic reticulum stress
• Activates the PERK/eIF2α/ATF4 signaling cascade
• ATF4 has been identified as the key pathway mediator through knockdown studies

Step 4: Apoptotic Execution

• ATF4 activation leads to CHOP and PUMA upregulation
• Increases pro-apoptotic Bax protein expression
• Decreases anti-apoptotic Bcl-2 and Bcl-xL proteins
• Results in mitochondrial membrane permeabilization and cell death

Mechanism 2: Calcium-Induced Apoptosis

Calcium Mobilization

• DH20931 promotes calcium release from the endoplasmic reticulum
• Demonstrates superior calcium-releasing capacity compared to thapsigargin
• CerS2 is critical for this calcium mobilization process

Mitochondrial Calcium Overload

• Released calcium flows into mitochondria
• Mitochondrial calcium overload triggers membrane permeabilization
• Results in cytochrome c release and caspase activation

Selectivity for Cancer Cells

The remarkable selectivity of DH20931 for cancer cells over healthy cells stems from the fundamental differences in CerS2 expression and ceramide metabolism between these cell types:

Cancer Cell Vulnerability:

• Reduced baseline CerS2 expression
• Impaired ceramide synthesis capacity
• Heightened sensitivity to ER stress
• Compromised calcium homeostasis

Normal Cell Resistance:

• Adequate CerS2 expression levels
• Robust ceramide synthesis capacity
• Efficient stress response mechanisms
• Maintained calcium homeostasis

---

Preclinical Efficacy Data

In Vitro Studies: Comprehensive Cell Line Testing

DH20931 has undergone extensive testing across multiple experimental systems, demonstrating consistent and potent anti-cancer activity:

Cytotoxicity Studies

TNBC Cell Lines:

• MDA-MB468: IC₅₀ = 5.22 ± 0.27 μM
• MDA-MB231: IC₅₀ = 4.02 ± 0.89 μM
• 4T1: IC₅₀ = 4.41 ± 0.60 μM

Other Breast Cancer Subtypes:

• MCF7 (Luminal A): IC₅₀ = 4.42 ± 0.67 μM
• JIMt1 (Luminal B): IC₅₀ = 4.3 ± 0.18 μM
• BT474 (Luminal B): IC₅₀ = 4.67 ± 0.12 μM

Normal Cell Selectivity:

• HMEpC (Normal Mammary Epithelial): IC₅₀ > 25 μM
• Demonstrates >5-fold selectivity for cancer cells

Three-Dimensional Spheroid Models

To better recapitulate the in vivo tumor environment, DH20931 was tested in three-dimensional spheroid culture systems:

Spheroid Formation Inhibition:

• Significant reduction in spheroid number
• Marked decrease in spheroid size
• Maintained activity in 3D environment confirms therapeutic potential

NCI-60 Cancer Cell Line Screen

DH20931 demonstrated broad-spectrum anti-cancer activity across the National Cancer Institute's 60 cancer cell line panel, representing multiple cancer types:

Tested Cancer Types:

• Colorectal cancer
• Ovarian cancer
• Prostate cancer
• Uterine cancer
• Bladder cancer
• Liver cancer
• Lung cancer
• Hematologic malignancies

Results: Consistent anti-proliferative activity across all tested cell lines, supporting the universal nature of the CerS2 pathway defect in cancer.

In Vivo Studies: Orthotopic and PDX Models

Orthotopic Breast Cancer Models

TNBC Model Results:

• Tumor Growth Inhibition: 80% reduction in tumor volume
• Tumor Concentration: ~4 μg/g drug concentration achieved in tumor tissue
• Treatment Duration: Sustained efficacy over 21-day treatment period

Luminal B Model Results:

• Tumor Growth Inhibition: 80% reduction in tumor volume
• Histological Analysis: Significant reduction in proliferative markers
• Vascular Effects: Reduced tumor angiogenesis

Patient-Derived Xenograft (PDX) Models

PDX models represent the gold standard for preclinical cancer drug testing, utilizing tumors directly derived from patient samples:

TNBC PDX (HCI-001):

• DH20931 IC₅₀: 1.02 μM
• Growth Inhibition: 80% reduction in tumor volume
• Histological Response: Extensive apoptotic cell death

HER2+ PDX (HCI-012):

• DH20931 IC₅₀: 3.07 ± 0.28 μM
• Cross-subtype Activity: Demonstrates efficacy beyond TNBC
• Therapeutic Window: Maintained selectivity for cancer cells

Combination Therapy Studies

One of the most promising aspects of DH20931 is its ability to enhance the efficacy of existing chemotherapy agents:

Doxorubicin Combination Studies

Mechanism of Synergy:

• DH20931 reduces cellular acidity, promoting doxorubicin uptake
• CerS2 activation enhances doxorubicin transport
• Dual apoptotic pathways create synergistic cell death

Efficacy Enhancement:

• 5-fold increase in doxorubicin efficacy
• Significant IC₅₀ reduction across all tested cell lines
• Dose-dependent synergy with 1 μM and 2.5 μM DH20931

Multi-Agent Combination Studies

Paclitaxel Combinations:

• Enhanced microtubule-stabilizing effects
• Increased apoptotic response
• Synergistic growth inhibition

Carboplatin Combinations:

• Enhanced DNA cross-linking efficacy
• Increased platinum uptake
• Improved therapeutic index

Gemcitabine Combinations:

• Enhanced nucleotide analog incorporation
• Increased DNA damage response
• Synergistic cell cycle arrest

---

Safety Profile

Preclinical Toxicology Studies

Comprehensive safety evaluation has been a cornerstone of DH20931 development, with extensive studies demonstrating an exceptional safety profile:

Acute Toxicity Studies

21-Day Intraperitoneal Treatment:

• Dose: 6 mg/kg body weight daily
• Duration: 21 consecutive days
• Observation: No signs of acute toxicity
• Tolerance: Well-tolerated at therapeutic doses

Hematological Safety Assessment

Comprehensive blood analysis using the HESKA Element HT5 Analyzer revealed no significant hematological toxicity:

Complete Blood Count Results:

Key Findings:

• No statistically significant changes in any hematological parameter
• No evidence of bone marrow suppression
• No signs of immune system dysfunction

Histopathological Analysis

Organ-Specific Toxicity Assessment:

• Liver: No hepatotoxicity observed
• Kidney: No nephrotoxicity detected
• Heart: No cardiotoxicity signs
• Lung: No pulmonary toxicity
• Brain: No neurotoxicity evidence
• Gastrointestinal: No GI toxicity

Histological Examination:

• Normal tissue architecture maintained
• No inflammatory infiltrates
• No cellular degeneration
• No fibrotic changes

Pharmacokinetic and ADME Properties

Pharmacokinetic Profile

Single-Dose Pharmacokinetics (6 mg/kg IP):

• Cmax: 486.16 ng/mL
• Tmax: Rapid absorption profile
• T½: 2.3 hours
• Bioavailability: Excellent systemic exposure

Tissue Distribution:

• Tumor Concentration: ~4 μg/g achieved without specific targeting
• Plasma Protein Binding: 56.9% ± 1.1% (favorable unbound fraction)
• Tissue Penetration: Excellent biodistribution to target tissues

ADME Characteristics

Absorption:

• Good membrane permeability
• Favorable bioavailability profile
• Rapid systemic distribution

Distribution:

• Moderate protein binding allows adequate free drug concentration
• Excellent tumor penetration
• Suitable volume of distribution

Metabolism:

• Good metabolic stability in liver microsome assays
• Predictable metabolic pathways
• No major metabolic liabilities identified

Excretion:

• Appropriate elimination half-life for therapeutic dosing
• No evidence of drug accumulation
• Suitable clearance profile

Transporter Studies

PAMPA Permeability:

• Low permeability compound profile
• Involvement of efflux transporters including P-glycoprotein
• Suitable for therapeutic applications

BCRP Transporter Studies:

• Not a substrate for Breast Cancer Resistance Protein
• Advantage in cancers with BCRP overexpression
• Maintains activity in drug-resistant tumors

---

Clinical Development Strategy

Phase I Clinical Trial Design

Based on the compelling preclinical data, DH20931 is positioned for clinical development with multiple strategic approaches under consideration:

Monotherapy First-in-Human Study

Study Design:

• Multi-histology dose-escalation study
• Starting dose based on preclinical safety data
• Built-in dose expansion cohorts
• Comprehensive safety and pharmacokinetic evaluation

Target Indications:

• Triple Negative Breast Cancer (primary)
• Other solid tumors (expansion cohorts)
• Dose-finding and preliminary efficacy assessment

Combination Therapy Approach

Doxorubicin Combination:

• Based on strong preclinical synergy data
• Potential for dose reduction of doxorubicin
• Reduced cardiotoxicity profile
• Enhanced therapeutic efficacy

Multi-Agent Combinations:

• Paclitaxel combination studies
• Carboplatin combination evaluation
• Gemcitabine combination assessment

Regulatory Strategy

Pre-IND Deliverables (Target: December 2026)

GLP Safety Studies:

• Comprehensive toxicology assessment
• Mutagenicity evaluation
• Cardiovascular safety pharmacology
• Pulmonary and CNS safety assessment

CMC Development:

• GMP manufacturing processes
• Analytical method development and validation
• Formulation optimization
• Stability studies

Pharmacology Studies:

• Transporter inhibition assessment
• Cross-species metabolism profiling
• Broad ligand screening
• Plasma protein binding studies

Clinical Trial Preparation

Key Opinion Leader Engagement:

• Identification of leading cancer centers
• Principal investigator recruitment
• Scientific advisory board formation
• Clinical protocol development

Manufacturing and Supply:

• GMP manufacturing partnerships
• Supply chain optimization
• Quality control procedures
• Regulatory compliance

---

Market Opportunity and Commercial Strategy

Market Size and Opportunity

Primary Market: Breast Cancer

Global Breast Cancer Market:

• Total Annual Cases: 2.3 million new cases (2022)
• TNBC Subset: 300,000 cases annually (10-15% of all breast cancers)
• Market Value: Multi-billion dollar therapeutic market
• Unmet Need: High due to limited effective treatments

Expanded Market: All Cancers

Broad Cancer Market Opportunity:

• Total Addressable Market: All solid tumors
• Hematologic Malignancies: Strong efficacy indications
• Cell Line Evidence: Positive results across 60+ cancer types
• Platform Potential: Single drug for multiple indications

Commercial Strategy

Phase 1: Breast Cancer Focus

Initial Market Entry:

• TNBC as primary indication
• Expand to all breast cancer subtypes
• Establish safety and efficacy profile
• Build clinical evidence base

Phase 2: Indication Expansion

Sequential Development:

• Colorectal cancer
• Ovarian cancer
• Prostate cancer
• Lung cancer
• Liver cancer
• Additional solid tumors

Phase 3: Platform Realization

Comprehensive Cancer Platform:

• Multiple indication approvals
• Combination therapy protocols
• Personalized medicine approaches
• Global market penetration

Partnership Strategy

Development Partnerships

World-Leading Cancer Institutes:

• Academic medical centers
• Comprehensive cancer centers
• Clinical research organizations
• Regulatory consultants

Manufacturing Partnerships:

• GMP manufacturing facilities
• Supply chain optimization
• Quality control systems
• Regulatory compliance

Licensing Strategy

Indication-Specific Licensing:

• License rights by cancer type
• Regional licensing agreements
• Milestone-based payments
• Royalty structures

Strategic Partnerships:

• Pharmaceutical company collaborations
• Co-development agreements
• Risk-sharing partnerships
• Market access arrangements

---

Financial Projections and Investment Requirements

Development Funding Requirements

Phase I Clinical Trial

Funding Requirement: $25 Million

• Clinical trial conduct
• Regulatory activities
• Manufacturing and supply
• Operational expenses

Use of Funds:

• Patient recruitment and treatment
• Clinical monitoring and data management
• Regulatory submission preparation
• Manufacturing scale-up

Future Development Phases

Phase II Studies: $50-75 Million

• Multiple indication studies
• Combination therapy protocols
• Expanded patient populations
• Regulatory interactions

Phase III Studies: $200-300 Million

• Pivotal efficacy studies
• Registration-enabling trials
• Commercial manufacturing
• Marketing preparation

Revenue Projections

Conservative Scenario: TNBC Only

Peak Annual Revenue: $2-3 Billion

• Based on 300,000 annual TNBC cases
• Assumed market penetration of 30-40%
• Premium pricing for novel mechanism

Optimistic Scenario: Multi-Indication Platform

Peak Annual Revenue: $15-20 Billion

• Multiple cancer indications
• Combination therapy protocols
• Global market penetration
• Platform technology value

Exit Strategy Options

Strategic Options

New Drug Approval:

• Retain full commercial rights
• Build commercial infrastructure
• Maximize long-term value
• Independent company growth

Indication-Specific Sales:

• Sell rights by indication
• Milestone and royalty payments
• Reduced development risk
• Multiple revenue streams

Complete Acquisition:

• Comprehensive platform sale
• Maximum short-term value
• Single transaction exit
• Immediate liquidity

---

Risk Assessment and Mitigation

Development Risks

Clinical Development Risks

Risk: Clinical trial failure Mitigation:

• Robust preclinical data package
• Experienced clinical development team
• Adaptive trial designs
• Multiple indication options

Risk: Regulatory delays Mitigation:

• Early FDA engagement
• Comprehensive regulatory strategy
• Experienced regulatory consultants
• Parallel regulatory submissions

Manufacturing Risks

Risk: Manufacturing scale-up challenges Mitigation:

• Early GMP development
• Experienced manufacturing partners
• Robust analytical methods
• Quality control systems

Risk: Supply chain disruptions Mitigation:

• Multiple supplier relationships
• Strategic inventory management
• Contingency planning
• Regional manufacturing

Commercial Risks

Market Competition

Risk: Competitive drug development Mitigation:

• Novel mechanism of action
• Patent protection
• First-mover advantage
• Broad indication potential

Risk: Market access challenges Mitigation:

• Health economic studies
• Payer engagement strategy
• Real-world evidence generation
• Value-based pricing

Technical Risks

Risk: Safety issues in clinical trials Mitigation:

• Comprehensive preclinical safety data
• Conservative dose escalation
• Rigorous safety monitoring
• Expert safety review board

Risk: Efficacy insufficient for approval Mitigation:

• Strong preclinical efficacy data
• Biomarker-driven patient selection
• Combination therapy options
• Adaptive trial designs

---

Conclusion

DH20931 represents a transformative advancement in cancer therapeutics, offering a novel mechanism of action that addresses fundamental vulnerabilities shared across virtually all cancer types. The compound's exceptional preclinical profile, characterized by potent anti-cancer activity, outstanding safety, and broad spectrum efficacy, positions it as a potential game-changer in oncology.

The CerS2 pathway represents an unexploited therapeutic target that offers unique advantages over current cancer treatments. By restoring the cancer cell's capacity for programmed cell death while preserving normal cell function, DH20931 addresses the fundamental challenge of cancer therapy: achieving selectivity for malignant cells.

The clinical development strategy for DH20931 is designed to maximize the compound's potential while minimizing development risks. Beginning with TNBC, a cancer type with significant unmet medical need, the development program will systematically expand to additional indications based on the compelling preclinical evidence for broad-spectrum activity.

The combination therapy potential of DH20931 adds another dimension to its therapeutic value. The ability to enhance the efficacy of existing chemotherapy agents while potentially reducing their toxicity profiles could revolutionize cancer treatment protocols and improve patient outcomes across multiple cancer types.

From a commercial perspective, DH20931 represents a rare opportunity to develop a truly platform technology in oncology. The potential for multiple indication approvals, combined with the compound's novel mechanism of action and favorable safety profile, creates a compelling investment opportunity with significant upside potential.

The funding requirement of $25 million for Phase I clinical trials represents a reasonable investment given the compound's exceptional preclinical profile and the size of the market opportunity. The potential for multiple exit strategies, from indication-specific licensing to complete platform acquisition, provides investors with multiple paths to value realization.

As the field of precision medicine continues to evolve, DH20931 stands as an example of how targeting fundamental cancer biology can lead to breakthrough therapeutic approaches. The compound's ability to address the metabolic vulnerabilities common to all cancers while maintaining an excellent safety profile represents the future of cancer treatment.

U.S. Precision Medicine is uniquely positioned to advance DH20931 through clinical development and into the market, bringing hope to cancer patients worldwide who currently have limited therapeutic options. The convergence of compelling science, significant market opportunity, and experienced management makes DH20931 a compelling investment opportunity in the rapidly evolving field of precision oncology.

---

References and Supporting Data

This white paper is based on proprietary research and development data from U.S. Precision Medicine, Inc. Additional scientific references and supporting data are available upon request for qualified investors and strategic partners.

---

Contact Information:

U.S. Precision Medicine, Inc.
Website: www.USPrecisionMedicine.com

Leadership Team:

• Mark Soberman, MD - Chief Medical Officer
• Satya Narayan, Ph.D. - Co-founder and Chief Scientific Officer
• Chris Fey - Co-founder
• Fred Fey - Co-founder

---

© 2025 U.S. Precision Medicine, Inc. All rights reserved. This document contains confidential and proprietary information and is intended for qualified investors and strategic partners only. Distribution or reproduction without written consent is strictly prohibited.